UPDATE: Onyx Pharma (ONXX) Shares Rise as Leerink Swann Upgrades to Outperform
Tweet Send to a FriendGet Alerts ONXX Hot Sheet
Price: $95.65 +0.31%
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ONXX Now!
(Updated - July 20, 2012 8:44 AM EDT)
Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) are trading up nearly 4 percent in Friday's pre-market session following an upgrade from Leerink Swann's Howard Liang.
The analyst now rates the stock an Outperform, up from Market Perform previously. The price target was lifted from $65 to $82.
Liang believes the failure of Bristol-Myers' (NYSE: BMY) brivanib creates a "significant positive for the long-term outlook of the Nexavar franchise." The analyst believes Onyx's "long-term outlook could be further enhanced by the opportunities for Nexavar in adjuvant liver cancer (STORM trial) and oral proteasome inhibitor oprozomib."
With shares of Onyx closing Thursday's session at $68.40, Leerink's new price target represents potential upside of about 20 percent.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) are trading up nearly 4 percent in Friday's pre-market session following an upgrade from Leerink Swann's Howard Liang.
The analyst now rates the stock an Outperform, up from Market Perform previously. The price target was lifted from $65 to $82.
Liang believes the failure of Bristol-Myers' (NYSE: BMY) brivanib creates a "significant positive for the long-term outlook of the Nexavar franchise." The analyst believes Onyx's "long-term outlook could be further enhanced by the opportunities for Nexavar in adjuvant liver cancer (STORM trial) and oral proteasome inhibitor oprozomib."
With shares of Onyx closing Thursday's session at $68.40, Leerink's new price target represents potential upside of about 20 percent.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Wells Fargo Downgrades Aruba Networks (ARUN) to Market Perform
- Stephens Upgrades Heartland Payment Systems (HPY) to Overweight
Create E-mail Alert Related Categories
Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
